NEW DATA EVALUATING LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS DEMONSTRATE NEUROPROTECTIVE EFFECTS

Data presented at the 26th Congress of the European Committee for Treatment and Research
in Multiple Sclerosis (ECTRIMS)

Jerusalem, Israel and Lund, Sweden, October 15, 2010 - Teva Pharmaceutical Industries
Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that
data providing further evidence of the neuroprotective properties of laquinimod in
animal studies were presented at the 26th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden. Laquinimod
is an investigational, once-daily oral immunomodulator for the treatment of relapsing
remitting multiple sclerosis (RRMS). 

These results, generated from several pre-clinical studies evaluating the mechanism of
action (MOA) of oral laquinimod, demonstrated that:

* 
Laquinimod reverts the disruption of neurogenic processes that can occur with chronic 
            inflammation in the central nervous system (CNS), and is associated with a
significant reduction 
            in the percentage of demyelination and axonal damage.  

* 
Laquinimod differentially influenced the activity of select immune cells, reducing their
pro-
            inflammatory characteristics while increasing the production of neurotrophic
factors known to be 
            involved in neuroprotection and repair mechanisms. 

* 
Laquinimod treatment is associated with an increase in brain-derived neurotrophic factor
(BDNF), 
            a pivotal factor in the development and maintenance of the CNS.

"These results add to the accumulating body of data establishing the novel MOA of
laquinimod. These MOA studies suggest that laquinimod has the potential to prevent
demyelination, which is associated with multiple sclerosis, and therefore may provide
neuroprotection in the treatment of RRMS," said Prof. Ralf Gold, Department of
Neurology, St. Josef-Spital, Ruhr University Bochum, Germany. "Research is ongoing to
further evaluate laquinimod, and we look forward to additional data, including the
forthcoming results from the Phase III clinical development program."

Laquinimod received Fast Track designation from the U.S. Food and Drug Administration
(FDA) in February 2009. Two global Phase III clinical studies, ALLEGRO and BRAVO, have
completed enrollment and are currently ongoing, with results anticipated in 2011.

ABOUT THE STUDIES

* 
[P885] Laquinimod prevents the inflammation-induced derangement of neurogenic niches  
            in experimental autoimmune encephalomyelitis mice.

Continue reading from Reuters